A Study to Assess Adverse Events and Disease Activity With Cedirogant (ABBV-157) in Adult Participants With Moderate to Severe Psoriasis

NCT05044234 · clinicaltrials.gov ↗

PHASE2

Phase

TERMINATED

Status

156

Enrollment

INDUSTRY

Sponsor class

Stopped Company Decision

Conditions

Psoriasis

Interventions

DRUG: Cedirogant
DRUG: Placebo

Sponsor

AbbVie